Biologic drugs in chronic spontaneous urticaria

Main Article Content

Amelia Licari
Sara Manti
Salvatore Leonardi
Domenico Minasi
Carlo Caffarelli
Fabio Cardinale
Michele Miraglia Del Giudice
Mauro Calvani
Giorgio Ciprandi
Gian Luigi Marseglia


Biologics, children, adult, chronic spontaneous urticaria, clinical trials


Chronic spontaneous urticaria (CSU) is a condition defined by the presence of recurrent urticaria, angioedema, or both, which persist for more than six weeks in duration and occurs in the absence of an identifiable trigger. Both children and adults can develop CSU, although it is more common in adults and in women than in men, with a peak occurrence in the third to fifth decades of life. It imposes a significant burden on patients, families and healthcare systems. The goal of therapy in patients with CSU is to achieve a level of symptom control and improvement in quality of life that is acceptable to the patient, while minimizing therapy-related side effects. The recent introduction of biologic drugs has changed the management of the disease. This work aims to provide a narrative review of the current state of biological therapy and the promising drugs under development for CSU.


Download data is not yet available.
Abstract 547 | PDF Downloads 237


1. Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy 2018;73:1393-1414.
2. Fricke J, Ávila G, Keller T, et al. Prevalence of chronic urticaria in children and adults across the globe: Systematic review with meta-analysis. Allergy 2020;75:423-32.
3. Licari A, Manti S, Marseglia A, et al. Biologics in Children with Allergic Diseases. Curr Pediatr Rev 2020;16:140-47.
4. Doong JC, Chichester K, Oliver ET, Schwartz LB, Saini SS. Chronic idiopathic urticaria: systemic complaints and their relationship with disease and immune measures. J Allergy Clin Immunol Pract 2017; 5:1314-18.
5. Sabroe RA, Seed PT, Francis DM, Barr RM, Black AK, Greaves MW. Chronic idiopathic urticaria: comparison of the clinical features of patients with and without anti-FcepsilonRI or anti-IgE autoantibodies. J Am Acad Dermatol 1999;40:443-50.
6. Rosman Y, Hershko AY, Meir-Shafrir K, et al. Characterization of chronic urticaria and associated conditions in a large population of adolescents. J Am Acad Dermatol 2019; 81:129-35.
7. Caffarelli C, Cuomo B, Cardinale F, et al. Aetiological factors associated with chronic urticaria in children: a systematic review. Acta Derm Venereol 2013;93:268-72.
8. Lachover-Roth I, Rabie A, Cohen-Engler A, Rosman Y, Meir-Shafrir K, Confino-Cohen R. Chronic urticaria in children - New insights from a large cohort. Pediatr Allergy Immunol 2021;32:999-1005.
9. Confino-Cohen R, Chodick G, Shalev V, Leshno M, Kimhi O, Goldberg A. Chronic urticaria and autoimmunity: associations found in a large population study. J Allergy Clin Immunol 2012;129:1307-13.
10. Kolkhir P, Borzova E, Grattan C, Asero R, Pogorelov D, Maurer M. Autoimmune comorbidity in chronic spontaneous urticaria: a systematic review. Autoimmun Rev 2017;16:1196-1208.
11. Altrichter S, Fok JS, Jiao Q, et al. Total IgE as a marker for chronic spontaneous urticaria. Allergy Asthma Immunol Res 2021;13:206-18.
12. Kolkhir P, Church MK, Weller K, Metz M, Schmetzer O, Maurer M. Autoimmune chronic spontaneous urticaria: what we know and what we do not know. J Allergy Clin Immunol 2017;139: 1772-81.
13. Saini SS, Paterniti M, Vasagar K, Gibbons SP Jr, Sterba PM, Vonakis BM. Cultured peripheral blood mast cells from chronic idiopathic urticaria patients spontaneously degranulate upon IgE sensitization: relationship to expression of Syk and SHIP-2. Clin Immunol 2009;132:342-48.
14. Tedeschi A, Kolkhir P, Asero R, et al. Chronic urticaria and coagulation: pathophysiological and clinical aspects. Allergy 2014;69:683-91.
15. Elias J, Boss E, Kaplan AP. Studies of the cellular infiltrate of chronic idiopathic urticaria: prominence of T-lymphocytes, monocytes, and mast cells. J Allergy Clin Immunol 1986;78:914-18.
16. Altrichter S, Frischbutter S, Fok JS, et al. The role of eosinophils in chronic spontaneous urticaria. J Allergy Clin Immunol 2020;145:1510-16.
17. Maurer M, Abuzakouk M, Bérard F, et al. The burden of chronic spontaneous urticaria is substantial: real-world evidence from ASSURE-CSU. Allergy 2017;72:2005-16.
18. Gonçalo M, Gimenéz-Arnau A, Al-Ahmad M, et al. The global burden of chronic urticaria for the patient and society. Br J Dermatol 2021;184:226-36.
19. Caffarelli C, Paravati F, El Hachem M, et al. Management of chronic urticaria in children: a clinical guideline. Ital J Pediatr 2019;45:101.
20. Xolair, INN-omalizumab. Available at: Last Access: August 2, 2021
21. Licari A, Castagnoli R, Denicolò C, et al. Omalizumab in children with severe allergic asthma: the italian real-life experience. Curr Respir Med Rev 2017;13:36-42.
22. Licari A, Manti S, Castagnoli R, et al. Targeted therapy for severe asthma in children and adolescents: current and future perspectives. Paediatr Drugs 2019;21:215-37.
23. Larenas-Linnemann DES, Parisi CAS, Ritchie C, et al. Update on omalizumab for urticaria: what's new in the literature from mechanisms to clinic. Curr Allergy Asthma Rep 2018;18:33.
24. Metz M, Torene R, Kaiser S, et al. Omalizumab normalizes the gene expression signature of lesional skin in patients with chronic spontaneous urticaria: A randomized, double-blind, placebo-controlled study. Allergy 2019;74:141-51.
25. Maurer M, Altrichter S, Bieber T, et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol 2011;128:202-09.
26. Maurer M, Rosén K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 2013;368:924-35. Erratum in: N Engl J Med 2013;368:2340-1.
27. Saini S, Rosen KE, Hsieh HJ, et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol 2011;128:567-73.
28. Saini SS, Bindslev-Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol 2015;135:925. Erratum in: J Invest Dermatol 2015;135:67-75.
29. Staubach P, Metz M, Chapman-Rothe N, et al. Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial. Allergy 2016;71:1135-44. Erratum in: Allergy 2017;72:1430.
30. Metz M, Staubach P, Bauer A, et al. Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin. Theranostics 2017;7:1266-76.
31. Jörg L, Pecaric-Petkovic T, Reichenbach S, et al. Double-blind placebo-controlled trial of the effect of omalizumab on basophils in chronic urticaria patients. Clin Exp Allergy 2018;48:196-204.
32. Hide M, Park HS, Igarashi A, et al. Efficacy and safety of omalizumab in Japanese and Korean patients with refractory chronic spontaneous urticaria. J Dermatol Sci 2017;87:70-78.
33. Maurer M, Kaplan A, Rosén K, et al. The XTEND-CIU study: long-term use of omalizumab in chronic idiopathic urticaria. J Allergy Clin Immunol 2018;141:1138-39.
34. Casale TB, Murphy TR, Holden M, Rajput Y, Yoo B, Bernstein JA. Impact of omalizumab on patient-reported outcomes in chronic idiopathic urticaria: results from a randomized study (XTEND-CIU). J Allergy Clin Immunol Pract 2019;7:2487-90.
35. Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol 2013;132:101-9.
36. Agache I, Rocha C, Pereira A, et al. Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: a systematic review for the EAACI Biologicals Guidelines. Allergy 2021;76:59-70.
37. Namazy J, Cabana MD, Scheuerle AE, et al. The Xolair pregnancy registry (EXPECT): the safety of omalizumab use during pregnancy. J Allergy Clin Immunol 2015;135:407-12.
38. Bernstein JA, Kavati A, Tharp MD, et al. Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic/spontaneous urticaria: a systematic review of 'real-world' evidence. Expert Opin Biol Ther 2018;18:425-48.
39. Fok JS, Kolkhir P, Church MK, Maurer M. Predictors of treatment response in chronic spontaneous urticaria. Allergy 2021.
40. Straesser MD, Oliver E, Palacios T, et al. Serum IgE as an immunological marker to predict response to omalizumab treatment in symptomatic chronic urticaria. J Allergy Clin Immunol Pract 2018;6:1386-88.
41. Marzano AV, Genovese G, Casazza G, et al. Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients. J Eur Acad Dermatol Venereol 2019;33:918-24.
42. Deza G, Bertolín-Colilla M, Pujol RM, et al. Basophil FcεRI expression in chronic spontaneous urticaria: a potential immunological predictor of response to omalizumab therapy. Acta Derm Venereol 2017;97:698-704.
43. Kolkhir P, Church MK, Altrichter S, et al. Eosinopenia, in chronic spontaneous urticaria, is associated with high disease activity, autoimmunity, and poor response to treatment. J Allergy Clin Immunol Pract 2020;8:318-25.
44. Türk M, Carneiro-Leão L, Kolkhir P, Bonnekoh H, Buttgereit T, Maurer M. How to treat patients with chronic spontaneous urticaria with omalizumab: questions and answers. J Allergy Clin Immunol Pract 2020; 8:113-24.
45. Metz M, Vadasz Z, Kocatürk E, Giménez-Arnau AM. Omalizumab updosing in chronic spontaneous urticaria: an overview of real-world evidence. Clin Rev Allergy Immunol 2020;59:38-45.
46. Netchiporouk E, Nguyen CH, Thuraisingham T, Jafarian F, Maurer M, Ben-Shoshan M. Management of pediatric chronic spontaneous and physical urticaria patients with omalizumab: case series. Pediatr Allergy Immunol 2015;26:585-88. Erratum in: Pediatr Allergy Immunol 2018;29:225.
47. Al-Shaikhly T, Rosenthal JA, Ayars AG, Petroni DH. Omalizumab for chronic urticaria in children younger than 12 years. Ann Allergy Asthma Immunol 2019;123:208-10.
48. Passanisi S, Arasi S, Caminiti L, Crisafulli G, Salzano G, Pajno GB. Omalizumab in children and adolescents with chronic spontaneous urticaria: Case series and review of the literature. Dermatol Ther 2020;33:e13489.
49. Ari A, Levy Y, Segal N, et al. Efficacy of omalizumab treatment for pediatric chronic spontaneous urticaria: A multi-center retrospective case series. Pediatr Dermatol 2020;37:1051-54.
50. Arm JP, Bottoli I, Skerjanec A, et al. Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects. Clin Exp Allergy 2014;44:1371-85.
51. Gauvreau GM, Arm JP, Boulet LP, et al. Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses. J Allergy Clin Immunol 2016;138:1051-59.
52. Maurer M, Giménez-Arnau AM, Sussman G, et al. Ligelizumab for chronic spontaneous urticaria. N Engl J Med 2019;381:1321-32.
53. Kay AB, Ying S, Ardelean E, et al. Elevations in vascular markers and eosinophils in chronic spontaneous urticarial weals with low-level persistence in uninvolved skin. Br J Dermatol 2014;171:505-11.
54. NUCALA® (mepolizumab) EMA approval. Available at: Last access: August 2, 2021.
55. Magerl M, Terhorst D, Metz M, et al. Benefit of mepolizumab treatment in a patient with chronic spontaneous urticaria. J Dtsch Dermatol Ges 2018;16:477-78.
56. Mepolizumab for the treatment of chronic spontaneous urticaria. Available at: Last Access: August 2, 2021.
57. European Medicines Agency. Available at: Last access: August 2, 2021.
58. Lee JK, Simpson RS. Dupilumab as a novel therapy for difficult to treat chronic spontaneous urticaria. J Allergy Clin Immunol Pract 2019;7:1659-61.
59. Errichetti E, Stinco G. Recalcitrant chronic urticaria treated with dupilumab: report of two instances refractory to H1-antihistamines, omalizumab and cyclosporine and brief literature review. Dermatol Ther 2021;34:e14821.
60. Dupilumab for the treatment of chronic spontaneous urticaria in patients who remain symptomatic despite the use of H1 antihistamine and who are naïve to, intolerant of, or incomplete responders to omalizumab (CUPID). Available at: Accessed on August 2, 2021.
61. Dupilumab in chronic spontaneous urticaria (DUPICSU). Available at: Accessed on August 2, 2021.
62. AstraZeneca. Fasenra (benralizumab) prescribing information. November, 2017. Available at: Accessed on August 2, 2021.
63. Treatment of chronic urticarial unresponsive to H1-antihistamines with an anti-IL5Ralpha monoclonal antibody. Available at: Accessed on August 2, 2021.
64. A study to investigate the use of Benralizumab in patients with chronic spontaneous urticaria who are symptomatic despite the use of antihistamines (ARROYO). Available at: Accessed on August 2, 2021.
65. Kay AB, Clark P, Maurer M, Ying S. Elevations in T-helper-2-initiating cytokines (interleukin-33, interleukin-25, and thymic stromal lymphopoietin) in lesional skin from chronic spontaneous ('idiopathic') urticaria. Br J Dermatol 2015;172:1294-302.
66. Study to evaluate Tezepelumab in adults with chronic spontaneous urticaria (INCEPTION). Available at: Accessed on August 2, 2021.
67. Magerl M, Philipp S, Manasterski M, Friedrich M, Maurer M. Successful treatment of delayed pressure urticaria with anti-TNF-alpha. J Allergy Clin Immunol 2007;119:752-54.
68. Wilson LH, Eliason MJ, Leiferman KM, Hull CM, Powell DL. Treatment of refractory chronic urticaria with tumor necrosis factor-alfa inhibitors. J Am Acad Dermatol 2011;64:1221-22.
69. Sand FL, Thomsen SF. TNF-alpha inhibitors for chronic urticaria: experience in 20 patients. J Allergy (Cairo) 2013;2013:130905.
70. Safety and efficacy of Abatacept in subjects with chronic urticaria who have had an inadequate response to anti-histamine therapy (TAHOE). available at: Accessed on August 2, 2021.
71. Townsend MJ, Monroe JG, Chan AC. B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol Rev 2010;237:264–83.
72. Arkwright PD. Anti-CD20 or anti-IgE therapy for severe chronic autoimmune urticaria. J Allergy Clin Immunol 2009;123:510-11.
73. Chakravarty SD, Yee AF, Paget SA. Rituximab successfully treats refractory chronic autoimmune urticaria caused by IgE receptor autoantibodies. J Allergy Clin Immunol 2011;128:1354-55.
74. Safety study of Rituximab (Rituxan®) in chronic urticaria. Available at: Accessed on August 2, 2021.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 11 > >>